Farhana F. Merzoug

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

David Schaer, Richard P. Beckmann, Jack Dempsey et al. · Cell Reports · 2018 · 460 citations · Full text

Medicine, Immunology, Pharmacology +17

Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib

Xueqian Gong, Lacey M. Litchfield, Yue Webster et al. · Cancer Cell · 2017 · 236 citations · Full text

Life Sciences, Genetics, Molecular Biology +14

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the <i>RB1</i> Tumor Suppressor Gene

Xueqian Gong, Jian Du, Stephen H. Parsons et al. · Cancer Discovery · 2018 · 233 citations

Life Sciences, Oncology, Pharmacology +17

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer

Emiliano Calvo, Victor J. Chen, Mark S. Marshall et al. · Investigational New Drugs · 2014 · 57 citations

Medicine, Oncology, Pharmacology +7

A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models

Xiang S. Ye, Fan Li, Robert D. Van Horn et al. · Molecular Cancer Therapeutics · 2015 · 31 citations

Medicine, Oncology, Pharmacology +13